Loading
Cancer, Lipids, and Metabolism · Journal article
International Journal of Molecular Sciences · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical in vitro mechanistic study demonstrating that docosahexaenoic acid enhances cytotoxicity of enzalutamide and a PARP inhibitor in two castration-resistant prostate cancer cell lines through differential modulation of cell death pathways. The findings are cell line–specific and pathway-focused, raising a hypothesis for further investigation but lacking evidence from animal models or human subjects necessary to inform clinical practice.
In vitro cell line study. Two castration-resistant prostate cancer cell lines (22Rv1 and PC3). Intervention: Docosahexaenoic acid (DHA) alone or combined with enzalutamide or PARP inhibitor AZD2461; wound-healing assays performed. Compared with: Enzalutamide or PARP inhibitor alone; vehicle or control conditions implied but not explicitly described.
DHA enhanced cytotoxic effect of PARP inhibitor AZD2461 in both 22Rv1 and PC3 cell lines DHA enhanced cytotoxic effect of enzalutamide in 22Rv1 cells but mechanism not described for PC3 cells In PC3 cells, DHA-mediated potentiation associated with downregulation of AKT pathway, reduced ERα, PPARγ, LXRβ, and shift toward necroptosis
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical finding is not yet translatable to clinical use. Substantial additional work—including animal models, pharmacokinetic studies, and eventually clinical trials—would be needed before considering DHA as an adjuvant to enzalutamide or PARP inhibitors in patients with CRPC.
In vitro mechanistic study in cancer cell lines showing DHA enhances cytotoxicity of existing drugs; no clinical evidence, animal models, or human data; raises questions about potential synergy requiring confirmation in vivo.
As stated by the source record.
This preclinical finding is not yet translatable to clinical use. Substantial additional work—including animal models, pharmacokinetic studies, and eventually clinical trials—would be needed before considering DHA as an adjuvant to enzalutamide or PARP inhibitors in patients with CRPC.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Docosahexaenoic acid (DHA), an omega-3 fatty acid, has emerged as a promising adjuvant treatment for castration-resistant prostate cancer (CRPC), but its interactions with current therapies remain unclear. This study investigated the antitumor effects of DHA alone or in combination with enzalutamide (ENZ) or the PARP inhibitor AZD2461 (iP) in CRPC cell lines 22Rv1 and PC3. DHA enhanced the cytotoxic effect of iP in both cell lines and of ENZ in 22Rv1 cells. In PC3 cells, DHA-mediated potentiation of iP cytotoxicity was associated with downregulation of the AKT pathway, reduced expression of ERα and the lipid sensors PPARγ and LXRβ, and a shift in programmed cell death toward necroptosis. In 22Rv1 cells, the additive effects of DHA with ENZ or iP were independent of PI3K/pAKT and AR-FL/AR-V7 modulation but were associated with regulation of LXRβ, PPARγ, and TNFR1, along with activation of apoptosis. Wound-healing assays showed that DHA blocked the anti-migratory effects of ENZ and iP in 22Rv1 cells and did not alter iP effects in PC3 cells, indicating epithelial–mesenchymal transition heterogeneity. Overall, DHA potentiates the cytotoxic effects of iP in both models and of ENZ in 22Rv1 cells via differential modulation of cell death in a molecular context-dependent manner.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.